LKT Laboratories, Inc.

SB-203580

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID S0500
CAS No. 152121-47-6
Chemical Name

Synonym SB203580

Formula $C_{21}H_{16}FN_3OS$
Formula Wt. 377.43
Melting Point
Purity ≥98%
Solubility

DMSO	43 mg/mL (113.92 mM)
Water	Insoluble
Ethanol	Insoluble

Store Temp -20°C
Ship Temp Ambient



Pricing and Availability

Bulk quanitites available upon request

Product ID	Size	List Price
S0500	5 mg	$60.20
S0500	25 mg	$208.70

Description SB-203580 is an inhibitor of p38 MAPK that exhibits immunostimulatory, anticancer, and anti-fibrotic activities. In peripheral blood mononuclear cells, SB-203580 increases secretion of IFN-γ. In lung epithelial cells, SB-203580 inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT). Additionally, SB-203580 inhibits proliferation in glioma cells and decreases angiotensin II- and TGF-β1-induced expression of GTGF and fibronectin in other cellular models.

References

Kühnöl C, Herbarth M, Föll J, et al. CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy. Cancer Immunol Immunother. 2013 Dec;62(12):1797-809. PMID: 24129764.

Chen HH, Zhou XL, Shi YL, et al. Roles of p38 MAPK and JNK in TGF-β1-induced human alveolar epithelial to mesenchymal transition. Arch Med Res. 2013 Feb;44(2):93-8. PMID: 23376055.

Morales MG, Vazquez Y, Acuña MJ, et al. Angiotensin II-induced pro-fibrotic effects require p38MAPK activity and transforming growth factor beta 1 expression in skeletal muscle cells. Int J Biochem Cell Biol. 2012 Nov;44(11):1993-2002. PMID: 22964022.